Christopher S. Burgey
About
Christopher S. Burgey is a scholar working on Organic Chemistry, Molecular Biology and Psychiatry and Mental health.
According to data from OpenAlex, Christopher S. Burgey has authored 40 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Organic Chemistry, 14 papers in Molecular Biology and 14 papers in Psychiatry and Mental health. Recurrent topics in Christopher S. Burgey's work include Migraine and Headache Studies (13 papers), Trigeminal Neuralgia and Treatments (8 papers) and Neuropeptides and Animal Physiology (7 papers). Christopher S. Burgey is often cited by papers focused on Migraine and Headache Studies (13 papers), Trigeminal Neuralgia and Treatments (8 papers) and Neuropeptides and Animal Physiology (7 papers). Christopher S. Burgey collaborates with scholars based in United States, United Kingdom and China. Christopher S. Burgey's co-authors include David A. Evans, Marisa C. Kozlowski, Steven W. Tregay, Kevin R. Campos, Tomáš Vojkovský, Nick A. Paras, Daniel V. Paone, James Z. Deng, Richard J. Staples and Jerry A. Murry and has published in prestigious journals such as Journal of the American Chemical Society, Neurology and Biochemistry.
In The Last Decade
Christopher S. Burgey
39 papers receiving 1.9k citations
Peers
Christopher S. Burgey
Daniel V. Paone United States
J. Delarge Belgium
Pauline Chiu Hong Kong
Duncan Shaw United Kingdom
Wenhu Duan China
Leggy A. Arnold United States
Shawn P. Maddaford Canada
Methvin Isaac Canada
Ruth E. TenBrink United States
T. G. Murali Dhar United States
Citations per year, relative to Christopher S. Burgey Christopher S. Burgey (= 1×)
peers
Daniel V. Paone
Countries citing papers authored by Christopher S. Burgey
Since
Specialization
Citations
This map shows the geographic impact of Christopher S. Burgey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher S. Burgey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher S. Burgey more than expected).
Fields of papers citing papers by Christopher S. Burgey
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Christopher S. Burgey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher S. Burgey. The network helps show where Christopher S. Burgey may publish in the future.
Co-authorship network of co-authors of Christopher S. Burgey
This figure shows the co-authorship network connecting the top 25 collaborators of Christopher S. Burgey. A scholar is included among the top collaborators of Christopher S. Burgey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher S. Burgey. Christopher S. Burgey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Vardigan, Joshua D., Xiaoping Zhou, Thomas W. Rosahl, et al.. (2025). Humanized NaV1.8 rats overcome cross-species potency shifts in developing novel NaV1.8 inhibitors. PubMed. 18. 100182–100182.
2.
Paone, Daniel V., Kausik K. Nanda, Jing Li, et al.. (2022). Lead optimization of cathepsin K inhibitors for the treatment of Osteoarthritis. Bioorganic & Medicinal Chemistry Letters. 74. 128927–128927.
3.
Roecker, Anthony J., M. E. Layton, Michael J. Kelly, et al.. (2021). Discovery of Arylsulfonamide Na v 1.7 Inhibitors: IVIVC, MPO Methods, and Optimization of Selectivity Profile. ACS Medicinal Chemistry Letters. 12(6). 1038–1049.
4.
Ballard, Jeanine, Joshua D. Vardigan, Fuqiang Zhao, et al.. (2021). Translational Pharmacokinetic–Pharmacodynamic Modeling of NaV1.7 Inhibitor MK-2075 to Inform Human Efficacious Dose. Frontiers in Pharmacology. 12. 786078–786078.
5.
Moore, Eric L., Mark E. Fraley, Ian M. Bell, et al.. (2020). Characterization of Ubrogepant: A Potent and Selective Antagonist of the Human Calcitonin Gene‒Related Peptide Receptor. Journal of Pharmacology and Experimental Therapeutics. 373(1). 160–166.
6.
Ballard, Jeanine, Joshua D. Vardigan, Fuqiang Zhao, et al.. (2020). Application of Pharmacokinetic-Pharmacodynamic Modeling to Inform Translation of In Vitro NaV1.7 Inhibition to In Vivo Pharmacological Response in Non-human Primate. Pharmaceutical Research. 37(10). 181–181.
7.
Moore, Eric L., Christopher S. Burgey, Mark E. Fraley, et al.. (2019). Characterization of Ubrogepant: A Potent and Selective Antagonist of the Human Calcitonin Gene-Related Peptide Receptor (P4.10-021). Neurology. 92(15_supplement).
8.
Crowley, Brendan M., et al.. (2011). Expanding the scope of the Cu assisted Suzuki–Miyaura reaction. Tetrahedron Letters. 52(39). 5055–5059.
9.
Trotter, B. Wesley, Kausik K. Nanda, Christopher S. Burgey, et al.. (2011). Imidazopyridine CB2 agonists: Optimization of CB2/CB1 selectivity and implications for in vivo analgesic efficacy. Bioorganic & Medicinal Chemistry Letters. 21(8). 2354–2358.
10.
Manley, Peter J., Daniel V. Paone, Christopher S. Burgey, et al.. (2011). Decahydroquinoline amides as highly selective CB2 agonists: Role of selectivity on in vivo efficacy in a rodent model of analgesia. Bioorganic & Medicinal Chemistry Letters. 21(8). 2359–2364.
11.
Paone, Daniel V., Diem N. Nguyen, Anthony W. Shaw, et al.. (2010). Orally bioavailable imidazoazepanes as calcitonin gene-related peptide (CGRP) receptor antagonists: Discovery of MK-2918. Bioorganic & Medicinal Chemistry Letters. 21(9). 2683–2686.
12.
Burgey, Christopher S., James Z. Deng, Scott D. Mosser, et al.. (2009). Optimization of azepanone calcitonin gene-related peptide (CGRP) receptor antagonists: Development of novel spiropiperidines. Bioorganic & Medicinal Chemistry Letters. 19(22). 6368–6372.
13.
Moore, Eric L., Christopher S. Burgey, Daniel V. Paone, et al.. (2008). Examining the binding properties of MK-0974: A CGRP receptor antagonist for the acute treatment of migraine. European Journal of Pharmacology. 602(2-3). 250–254.
14.
Paone, Daniel V., Anthony W. Shaw, Diem N. Nguyen, et al.. (2007). Potent, Orally Bioavailable Calcitonin Gene-Related Peptide Receptor Antagonists for the Treatment of Migraine: Discovery of N -[(3 R ,6 S )-6-(2,3-Difluorophenyl)-2-oxo-1- (2,2,2-trifluoroethyl)azepan-3-yl]-4- (2-oxo-2,3-dihydro-1 H -imidazo[4,5- b ]pyridin- 1-yl)piperidine-1-carboxamide (MK-0974). Journal of Medicinal Chemistry. 50(23). 5564–5567.
15.
Salvatore, Christopher, James C. Hershey, John F. Fay, et al.. (2007). Pharmacological Characterization of MK-0974 [N-[(3 R,6 S)-6-(2,3-Difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1 H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide], a Potent and Orally Active Calcitonin Gene-Related Peptide Receptor Antagonist for the Treatment of Migraine. Journal of Pharmacology and Experimental Therapeutics. 324(2). 416–421.
16.
Shaw, Anthony W., Daniel V. Paone, Diem N. Nguyen, et al.. (2007). Caprolactams as potent CGRP receptor antagonists for the treatment of migraine. Bioorganic & Medicinal Chemistry Letters. 17(17). 4795–4798.
17.
Deng, James Z., Daniel R. McMasters, Peter Williams, et al.. (2005). Development of an oxazolopyridine series of dual thrombin/factor Xa inhibitors via structure-guided lead optimization. Bioorganic & Medicinal Chemistry Letters. 15(20). 4411–4416.
18.
Lin, Charles C., Bradley K. Wong, Christopher S. Burgey, Christopher R. Gibson, & Rominder Singh. (2005). In vitro metabolism of a thrombin inhibitor and quantitation of metabolically generated cyanide. Journal of Pharmaceutical and Biomedical Analysis. 39(5). 1014–1020.
19.
Evans, David A., Jeffrey S. Johnson, Christopher S. Burgey, & Kevin R. Campos. (1999). Reversal in enantioselectivity of tert-butyl versus phenyl-substituted bis(oxazoline) copper(II) catalyzed hetero Diels-Alder and ene reactions. Crystallographic and mechanistic studies. Tetrahedron Letters. 40(15). 2879–2882.
20.
Evans, David A., Marisa C. Kozlowski, Jerry A. Murry, et al.. (1999). C2-Symmetric Copper(II) Complexes as Chiral Lewis Acids. Scope and Mechanism of Catalytic Enantioselective Aldol Additions of Enolsilanes to (Benzyloxy)acetaldehyde. Journal of the American Chemical Society. 121(4). 669–685.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Daniel V. Paone Breakdown of academic impact, for papers by J. Delarge Breakdown of academic impact, for papers by Pauline Chiu Breakdown of academic impact, for papers by Duncan Shaw Breakdown of academic impact, for papers by Wenhu Duan Breakdown of academic impact, for papers by Leggy A. Arnold Breakdown of academic impact, for papers by Shawn P. Maddaford Breakdown of academic impact, for papers by Methvin Isaac Breakdown of academic impact, for papers by Ruth E. TenBrink Breakdown of academic impact, for papers by T. G. Murali Dhar